IANAL
The NYT is reporting that the preemption legal theory (here, the idea that regulatory approval shields a company from liability) has a rather decent chance of winning in the Ortho Evra case. I have previously discussed the merits (and limits) of such a theory. I am confused as to how anyone can take seriously the [...]
Just a note, I am not a lawyer (IANAL), but I have worked for several years on lawsuits involving pharmaceutical companies, the FDA, the USPTO, wholesalers, retailers, and consumers. Take the comments into account accordingly.
If only our regulatory and publishing systems were so good. I understand the sentiment expressed, and things are moving in the [...]
I haven’t written much about e-voting initiatives, and there is too much to be written in a single space. But a few quick thoughts before passing you on to the well-versed Stokes. Avoiding the technical issues of which I am not capable of commenting on intelligently, the economic issues in these devices and processes are [...]
This work is licensed under
CC Attribution-Noncommercial-Share Alike 3.0 unless otherwise specified.
This software is licensed under the CC-GNU GPL unless otherwise specified.
Atom/RSS Syndication
Comments Atom/RSS
